Sasidharan Shan, Kaveri Asha Nair, Sithara M S, Nair J Hareendran
Department of R&D, Pankajakasthuri Herbal Research Foundation, Thiruvananthapuram, Kerala, India.
Small Animal Research Centre, Department of Toxicology and Pharmacology, CARe KERALA, Thrissur, Kerala, India.
J Exp Pharmacol. 2023 Mar 27;15:149-161. doi: 10.2147/JEP.S402277. eCollection 2023.
Local anaesthetics are medications that cause numbness that can be reversed by applying them topically. Local anaesthetics are clinically used to control pain during minor surgeries or to treat other acute and chronic pain. The present investigation intended to investigate the anesthetic as well as analgesic potential of Injection Harsha 22, a novel polyherbal formulation in Wistar albino rats.
The anesthetic potential of Injection Harsha 22 was evaluated by a heat tail-flick latency (TFL) test, whereas the analgesic effect was elevated by electrical stimulation testing. Here, lignocaine (2%) was used as the standard anesthetic drug.
In TFL, Injection Harsha 22 showed anesthetic effects up to 90 minutes after application. Also, the duration of anesthesia in rats that were administered subcutaneously with Injection Harsha 22 was comparable to that of the rats treated with commercial lignocaine (2%). In an electrical stimulation test, single administration of Injection Harsha 22 to rats significantly prolonged analgesia compared with the normal control group. The median duration of analgesia in rats administered subcutaneously with Injection Harsha 22 and lignocaine solution was 40 minutes and 35 minutes, respectively. Furthermore, Injection Harsha 22 does not interfere with the hematopoietic system of the experiment animals.
Thus, the present investigation established the in vivo anesthetic and analgesic potential of Injection Harsha 22 in experimental animals. Hence, it can be concluded that Injection Harsha 22 can become a prominent substitute for lignocaine as a local anaesthetic agent after establishing its efficacy through stringent clinical trials in humans.
局部麻醉药是一类能引起麻木感且可通过局部应用使其作用逆转的药物。局部麻醉药在临床上用于控制小型手术中的疼痛或治疗其他急慢性疼痛。本研究旨在探究一种新型多草药制剂哈莎22注射液在Wistar白化大鼠体内的麻醉及镇痛潜力。
通过热甩尾潜伏期（TFL）试验评估哈莎22注射液的麻醉潜力，而镇痛效果则通过电刺激试验来提升。在此，2%的利多卡因被用作标准麻醉药物。
在TFL试验中，哈莎22注射液在应用后长达90分钟显示出麻醉效果。此外，皮下注射哈莎22注射液的大鼠的麻醉持续时间与接受商用2%利多卡因治疗的大鼠相当。在电刺激试验中，与正常对照组相比，单次给大鼠注射哈莎22注射液可显著延长镇痛时间。皮下注射哈莎22注射液和利多卡因溶液的大鼠的镇痛中位持续时间分别为40分钟和35分钟。此外，哈莎22注射液不干扰实验动物的造血系统。
因此，本研究证实了哈莎22注射液在实验动物体内的体内麻醉和镇痛潜力。因此，可以得出结论，在通过严格的人体临床试验确立其疗效后，哈莎22注射液可成为利多卡因作为局部麻醉剂的一种重要替代品。
